Ebola:Liberian doctor Dies after ZMapp failed to cure him

A Liberian doctor who was among three Africans to receive an experimental Ebola drug has died, it was announced today.
Dr Abraham Borbor, the deputy chief medical doctor at the country's largest hospital in Monrovia, had been among three Liberians - and the first Africans - who received the drug, ZMapp.
He worked at the John F. Kennedy Medical Center in the country's capital.
Initial reports suggested all three recipients of the drug had responded well after receiving the drug on August 13.But Dr Borbor yesterday took a turn for the worse, the country's Information Minister Lewis Brown told The Associated Press.

Two Americans, Dr Kent Brantly and aid worker Nancy Writebol, received the untested drug and survived.
But a Spanish missionary infected with Ebola died after receiving the treatment - and there has been no update on the two other Liberians who took doses of it.

                          
Ebola has killed more than 1,400 people across West Africa. There is no proven vaccine or cure for the disease that can cause a grisly death with bleeding from the eyes, mouth and ears.
The virus can only be transmitted through direct contact with the bodily fluids of the sick or from touching victims' bodies, leaving doctors and other health care workers most vulnerable to contracting it.
The first British victim, nurse William Pooley, is now being treated in an isolation unit in London's Royal Free Hospital.
The 29-year-old had selflessly volunteered to serve in a makeshift clinic in Sierra Leone where other nurses had died from Ebola or were too scared to come into work.
Mr Pooley last night arrived back to London after being airlifted in an isolation sack for treatment at the north London hospital.
Last night the NHS started a global hunt for remaining supplies of the only treatment thought to combat the virus - ZMapp.

                       
The drug had never been tested on humans, although an early version had been found to work in some ebola-infected monkeys.
It is aimed at boosting the immune system's efforts to fight the disease.
Only five people in the world are known to have received the drug and Mapp Biopharmaceutical, the American company behind it, says stocks are exhausted.
It is expected to be months before more can be produced by its U.S. maker.
Health experts caution that the drug had never been tested in humans before and it was unclear whether it works.

They also say there is a huge gap between the treatment the two Americans got at an Atlanta hospital, where five infectious disease experts and 21 nurses provided rigorous care, and West Africa, where even such basics as sterile fluids can be in short supply.
Earlier today, Japanese officials said they were ready to provide an anti-flu drug as a potential treatment to the deadly disease.